

Original research Articles

COMPARATIVE ANALYSIS OF CERVICAL HUMAN PAPILLOMAVIRUS DNA TESTING AND CYTOLOGICAL FINDINGS AMONG WOMEN PRESENTING FOR PAP SMEAR IN A TERTIARY HEALTH CENTRE IN NORTHERN NIGERIA

ABSTRACT

Aim: This study was conducted to compare different cytological findings with cervical HPV infection among women presenting for cervical cancer screening in Gombe north-eastern Nigeria.

Study design: It is a hospital based cross-sectional study.

Place and Duration of Study: Departments of Obstetrics/Gynaecology and Histopathology Federal Teaching Hospital Gombe (FTHG) Nigeria, between August 2013 and May 2014.

Methodology: Two hundred and nine (209) women were subjected to cervical cytology and HPV DNA testing.

Results: Normal cytological findings were observed among 126 (61.6%) participants while 80 (39.0%) had abnormal features and 3 (1.4%) had unsatisfactory smears. The abnormal cytological features were HPV changes 30 (14.4%), HPV changes with inflammation 2 (1.0%), inflammatory changes alone 36 (17.3%), LSIL 3 (1.4%), HSIL 5 (2.4%) and malignant changes 3 (1.4%). HPV DNA was detected among 100 (48.1%) of the participants. Almost half 60 (47.6%) of the women with normal cytology were positive for HPV while half (16) of the smears with cytologic HPV changes were also HPV DNA positive. The sensitivity and specificity of cervical cytology in detecting HPV infection was 16.2% and 85.0% respectively.

Conclusion: This study reports a very low sensitivity but relatively high specificity of cytology in detecting cervical HPV infection. It further justifies the need for HPV DNA testing in cervical cancer screening for developing countries.

Key words: cervical cancer, cytology, human Papillomavirus, DNA testing, Nigeria

1. INTRODUCTION

Human Papillomaviruses (HPVs) have remained a serious global health problem due to their association with anogenital/oral cancers and warts.[1] Infection with HPV is the major risk factor for cervical cancer as more than 99% of all cases contain the high risk (hr) HPV.[2] Beside being the commonest sexually transmitted infection (STI), infection of the genital tract with HPV is commoner among young sexually active women.[3] In some studies, up to 70% of college-aged women are found to be HPV DNA positive. Its probability increases with increasing number of lifetime sexual partners. Fortunately, most HPV infections in young women (below 30 years) are transient and it is only the small proportion of women who become persistently infected with hr-HPV that remain at risk for the subsequent development of CIN or cervical cancer.[4] Cervical cancer is the second most

common cancer in women worldwide, the leading cause of cancer deaths in developing countries but is gradually becoming a rare disease in many developed countries.[5] In Nigeria, cancer of the uterine cervix is the most common genital tract malignancy in northern region.[6][7] This has made studies on HPV in relation to cervical cancer screening even more important in the region. Screening with cervical cytology at regular intervals has globally formed the basis for cervical cancer prevention.[8] The Papanicolaou ("Pap") smear is a simple and well-accepted procedure for efficient detection of potentially premalignant HPV-associated cervical lesions through cytological examination of exfoliated cervical cells.[9] However, the need for repeated screening cycles makes cytology-based cervical cancer screening programmes expensive.[10] Moreover, this conventional screening model (Pap smear followed by colposcopically directed biopsy) is neither sufficiently developed nor sustainable in most countries with limited resources.[11] The newer Liquid-based cytology (LBC) has replaced conventional Papanicolaou cytology as the platform for cervical cytology in a number of developed countries. Advantages of LBC include more rapid screening of slides, a substantial reduction in unsatisfactory cervical samples requiring repeat testing, and a cellular residue suitable for HPV testing.[3] However, even such improved cytology tests may miss 15% to 35% of CIN III or cancer in a routine screening setting.[12]

In this study we compared cervical oncogenic HPV infection with various findings from LBC among women who presented for routine cervical cancer screening at the Federal Teaching Hospital Gombe (FTHG), North-eastern Nigeria.

2. MATERIAL AND METHODS

2.1 STUDY DESIGN AND POPULATION

The study was an observational hospital based cross sectional study among 209 women who presented for cervical cancer screening (using LBC) at the FTHG between August 2013 and May 2014. Women who gave an informed consent for HPV DNA testing among those presenting for cervical cancer screening were counselled and recruited for the study. Ethical clearance was obtained from the research and ethics committee of FTHG.

2.2 SPECIMEN COLLECTION, PRESERVATION AND PROCESSING

Cervical cells were obtained using Rovers® Cervex-Brush® cell sampling device (Rovers Medical Devices B.V 5347 KV Oss, The Netherlands). The brush was subsequently transferred into the preservative fluid of a liquid-based cytology system; *Liqui-PREP* (LGM International, Inc, Melbourne, FL, USA).

DNA extraction for the PCR was done using proteinase K digestion, followed by phenol/chloroform and ethanol precipitation method.

Polymerase Chain Reaction (PCR) for the detection of oncogenic HPV was done using the GP5+/GP6+ (GP5+ [5' TTTGTTACTGTGGTAGATACTAC-3'] and GP6+ [5'-GAAAAATAAACTGTAAATCATATTC-3']) consensus primers which amplifies a 150bp fragment of the

L1 HPV genomic region.[13] AccuPower HotStart Premix (Bioneer Corporation, South Korea) was used for the PCR. Target amplicons were identified on a 2% agarose gel after electrophoresis. Cervical cytological findings were reported by a cytopathologist using the 2001 Bethesda system independent of the HPV status of the participants.

Laboratory procedures were carried out at the departments of Histopathology FTHG and the DNA Labs, Kaduna, Nigeria.

2.3 DATA ANALYSIS

Statistical data analysis was done using the Statistical Package for the Social Sciences version 22 (SPSS Inc., Illinios, USA). Data entry in to the SPSS was done using numeric codes. Student's *t* test was used to derive mean, standard deviation and test of comparison for continuous variables. Categorical variables were summarized as proportions and further analyzed using Chi square to assess association between them. Sensitivity, specificity, Positive predictive value (PPV) and Negative predictive value (NPV) were calculated using the formulae; $TP/TP+FN$, $TN/TN+FP$, $TP/TP+FP$ and $TN/TN+FN$ respectively. Tables and charts were appropriately used to represent the analyzed data.

3. RESULTS AND DISCUSSION

3.1 RESULTS

Two hundred and nine (209) women whose mean age was 39.6 ± 0.72 years were studied out of which 208 had both cytology and HPV DNA detection done on their specimens. Majority 166 (79.8%) of the respondents were above 30 years of age as only 42 (20.2%) were 30 years and below. Cytologically, more than half 126 (61.6%) of participants had normal findings but up to 80 (39.0%) had abnormal features while 3 (1.4%) specimens had unsatisfactory smears for cytologic studies. The abnormal cytological features observed were HPV changes 30 (14.4%), HPV changes with inflammation 2 (1.0%), inflammatory changes alone 36 (17.3%), LSIL 3 (1.4%), HSIL 5 (2.4%) and malignant changes 3 (1.4%). (Figure 1)




Figure 1: Cytological findings among the participants (N=208)

Cervical HPV infection based on presence of DNA was detected among 100 (48.1%) of the participants. Table 1 shows the distribution of HPV DNA among women with normal and abnormal cytological findings. Of the 99 participants who had cytology reports and tested positive for HPV, 60 (60.6%) had normal cytologic findings while 39 (39.4%) had abnormal smears.

Table 1: Distribution of HPV DNA among women with normal and abnormal cytological findings

	HPV DNA Positive	HPV DNA Negative	Total
Normal Cytology	60 (60.6%)	65 (61.3%)	125
Abnormal Cytology	39 (39.4%)	41 (38.7%)	80
Total	99	106	205

The mean age of women with cytological HPV changes (34.81 ± 8.96 years) was significantly lower compared to those with other cytological findings (40.40 ± 10.47 years) among the participants ($P = .005$). The mean age of women found to be positive for HPV DNA was only slightly higher; $40.79 (\pm 11.23)$ years compared to $38.49 (\pm 9.47)$ years among those with no HPV infection. ($P = .111$). Association between women with HPV infection and those with cytologically detected HPV changes, normal or other abnormal results did not show statistical significance ($\chi^2 = 3.323$, $P = .344$). Almost half 60 (47.6%) of the 127 women with normal cytology were positive for HPV and exactly half 16 (50.0%) of the 32 respondents with cytologic HPV changes were also HPV DNA positive. Among women with cytological inflammatory features alone, 15 (41.7%) of the 36 had HPV infection. Pre-malignant (LSIL and HSIL) and malignant cervical lesions carried the highest percentage of HPV infection as 8 (72.7%) out of 11 were positive for HPV. (Table 2)

Table 2: Association between cervical HPV infection and cytological findings

Cytology	Presence of HPV DNA		Total	χ^2	P value
	Positive N (%)	Negative N (%)			
Normal	60 (47.6%)	66 (52.4%)	126 (100%)	4.852	0.678
HPV Changes	15 (50.0%)	15 (50.0%)	30 (100%)		
HPV changes+inflammation	01 (50.0%)	01 (50.0%)	02 (100%)		
Inflammatory	15 (41.7%)	21 (58.3%)	36 (100%)		
LSIL	03 (100%)	00 (0.00%)	03 (100%)		
HSIL	03 (60.0%)	02 (40.0%)	05 (100%)		
Malignant	02 (66.7%)	01 (33.3%)	03 (100%)		

There was no statistically significant association between PCR detected HPV infection and the cytologically detected cervical lesions ($\chi^2 = 4.852$; $P = .678$). Tables 3 compared the HPV DNA results based on PCR with cytologically detected HPV changes among the participants. Taking PCR as the gold standard for HPV detection, cytologic HPV changes showed a very low sensitivity of 16.2% but higher specificity of 85.0%. Positive predictive value (PPV) and Negative predictive value (NPV) for cytologically detected HPV changes were found to be 50% and 52% respectively.

Table 3: Comparison of HPV positivity by cervical smear cytology and PCR among the participants

	HPV DNA Positive	HPV DNA Negative	Total
Cytology Positive	16 (TP)	16 (FP)	32

Cytology Negative	83 (FN)	90 (TN)	173
Total	99	106	205

(TP: True Positive; TN: True Negative; FP: False Positive; FN: False Negative)

Sensitivity = $TP/TP+FN = 16/16+83 = 0.162 = 16.2\%$

Specificity = $TN/TN+FP = 90/16+90 = 0.850 = 85.0\%$

Positive predictive value (PPV) = $TP/TP+FP = 16/16+16 = 0.50 = 50\%$

Negative predictive value (NPV) = $TN/TN+FN = 90/90+83 = 0.52 = 52\%$

3.2 DISCUSSION

Presently, cervical screening for carcinogenic HPV infection is being considered in lieu of cytology even for low-income countries.[11] Negative cytology provides no extra reassurance against cancer beyond that conferred by a negative HPV test result.[14] Also, only about a third of women with HPV infections detectable by DNA testing have recognised cytopathology. Therefore, cytological abnormalities are less sensitive for detection of HPV than molecular testing. Assays for HPV have been introduced to improve the efficiency and maximise the sensitivity of cervical cancer screening. Most importantly, testing negative for carcinogenic HPV provides greater reassurance against cervical pre-cancer/cancer and has greater reproducibility than does cytology-based methods.[10] DNA testing for HPV although substantially more sensitive is somewhat less specific[4] than cervical cytology for the detection of CIN2, CIN3 and cancer. A single negative test for HPV is sufficient to reassure women against cervical cancer over 5 years as they have low risk of CIN3 or cancer during that period regardless of cytological findings.[14] The International Agency for Research on Cancer has endorsed the use of carcinogenic HPV testing alone as an option in primary cervical cancer screening.[10] Testing for HR-HPV is mandatory for women with mild dyskaryosis and for the follow-up of women treated for CIN lesions.[15]

Based on efficiency to detect CIN3/cervical cancer and preliminary cost benefit analysis, the combination of a high risk HPV test in conjunction with a cervical smear appears to be the best way of cervical cancer screening.[15] Incorporating HPV testing with cytology could also result in earlier identification of women at high risk of cervical cancer, especially adenocarcinoma (the precursors of which are often missed by cytological methods) and could reduce the incidence of this cancer in women aged 30 years and older.[14] It also predicts increased risk up to ten years later (i.e., a high negative predictive value[16]) and is amenable to self-sampling outside the clinic, which allows expanded population coverage.[11][8] The interpretation of the test is objective and does not have the inherent subjectivity of visual screening methods or cervical cytologic assessment.[4]

Different reports have highlighted the supplementary role of HPV DNA testing in primary/secondary cervical cancer screening with more promising outcomes.[17][18] The utility/acceptability of HPV DNA testing in cervical cancer screening has shown better prospects with introduction of self sampling techniques and use of other body fluids (e.g. urine) in detecting the virus.[19][20] This may obviate

several hindrances to cervical cancer screening that may be due to socio-cultural and/or religious issues reducing the acceptability of current conventional screening method. It has recently been posited that cervical cancer screening using HPV DNA testing might overtake conventional cytology and cost countries less money while providing greater safety.[21][22]

Several studies from Nigeria had reported varying prevalences of cervical HPV infection among different population groups. However very scanty literature is available to compare the presence of cervical HPV infection with corresponding cytopathological features especially in Northern Nigeria where cervical cancer is more prevalent.

The age group of participants from this study with majority being above 30 years of age makes them suitable for the use of HPV DNA as an appropriate tool for cervical cancer screening. This is buttressed by the fact that majority of those with positive DNA test may be harbouring a persistent infection which is the major risk factor for the development of cervical cancer.[2]

Out of 99 participants who were HPV DNA positive and also had cytology reports, more than half (60.6%) revealed normal cytological findings while 39 (39.4%) showed abnormal features cytologically. This means up to 21.2% (21) of women with confirmed HPV infection did not show any cytologic abnormality. This conforms to some findings that reported up to 15% to 35% of women with CIN 3 or even cancer being missed by cervical cytology.[12] In another study, 15.1% of women above 30 years of age with persistent hr-HPV infection were preceded by normal cytology.[23] It makes imperative the need for additional or alternative method for cervical cancer screening aside cervical cytology. Combination of hr-HPV testing and cytology provides the best option for screening even in low resource settings as northern Nigeria.[24] Additionally, incorporation of HPV testing in cervical cancer screening will even lead to better detection of particularly adenocarcinoma whose precursors are often missed by cytological methods.[14]

A high prevalence (72.7%) of HPV infection was observed among women with either premalignant (LSIL or HSIL) or malignant cervical lesions. Persistent HPV infection is a well known precursor of both premalignant and malignant cervical lesions. A study in France reported up to 82% HPV positivity among women with CIN 2/3.[25] Almost half (41.7%) of the women with cervical inflammation without HPV changes observed in this study were HPV DNA positive. Infections including HPV are a common cause of cervical inflammation. Cervical inflammation has been found to be likely associated with high-grade lesions with a possibility of being a cofactor for high-grade cervical lesions in women infected with oncogenic HPV.[26]

We observed that only 50% of women with PCR confirmed HPV infection were found to have corresponding cytologic changes suggestive of the infection. This may not be unconnected with the fact that clearance of cervical HPV infection precedes cytologic regression and only about a third of women with HPV infection have recognised cytopathology.[10][27] This may be supported by the relative low sensitivity (16.2%) and higher specificity (85.0%) of cervical smear cytology in detecting cervical HPV infection compared to PCR (which is the gold standard) which is also not unusual. [4][10]

The positive predictive value (PPV) of 50% and negative predictive value (NPV) of 52% further reaffirms that barely half of all women with or without HPV infection were picked or ruled out by cervical cytology. It has portrayed the poor performance of cervical cytology in detecting HPV infection while further justifying the need to add HPV detection in primary cervical cancer screening especially for women above 30 years of age in whom persistence of the infection may eventually translate in cervical cancer.

Granted that we have not carried out colposcopy or histology on the participants as such could not confirm the presence of cervical lesions, HPV testing in conjunction with cytology has been reported to improve the screening efficacy of cytology alone while allowing for a more effective and safe primary screening program with increased screening intervals.[23][28]

4. CONCLUSION

In conclusion, the fact that combining cytology and hr-HPV testing is not likely to miss any clinically relevant cervical lesion in addition to offering longer screening intervals makes it the best cervical cancer screening option even in developing countries. With the recent additions including the use of other specimens like urine, swabs for cervical self-sampling and automation of HPV testing methods that require little or no training even by unskilled personnel, the future of HPV testing holds promise in cervical cancer screening.

REFERENCES

- [1] Seaman WT, Andrews E, Couch M, Kojic EM, Cu-Uvin S, Palefsky J, et al. Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. *Virology* 2010 Aug; 7(1):194.
- [2] Levert M, Clavel C, Graesslin O, Masure M, Birembaut P, Quereux C, et al. Human papillomavirus typing in routine cervical smears. Results from a series of 3778 patients. *Gynécologie Obstétrique Fertil* 2000 Oct; 28(10):722–8.
- [3] Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. *Lancet Oncol* 2009 Jul; 10(7):672–82.
- [4] Villa L, Denny L. Methods for detection of HPV infection and its clinical utility. *Int J Gynecol Obstet* 2006; 94(Suppl 1):71–80.
- [5] Anorlu RI. Cervical cancer: the sub-Saharan African perspective. *Reprod Health Matters* 2008; 16(32):41–9.
- [6] Pindiga UH, El-Nafaty AU, Ekanem IA. Female genital malignancies in Maiduguri, Nigeria. A review of 328 cases. *Trop J Obstet Gyn* 1999; 16:52–6.
- [7] Yakasai I, Ugwa E, Otubu J. Gynecological malignancies in Aminu Kano Teaching Hospital Kano: A 3 year review. *Niger J Clin Pract* 2013; 16(1):63.
- [8] Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. *Eur J Cancer* 2011 Apr; 47(6):864–71.

- 248 [9] McLaughlin-Drubin ME, Munger K. Oncogenic Activities of Human Papillomaviruses. *Virus Res*
249 2009 Aug; 143(2):195–208.
- 250 [10] Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and
251 cervical cancer. *The Lancet* 2007 Sept; 370(9590):890–907.
- 252 [11] Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, et al. The age-specific
253 prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications
254 for screen-and-treat strategies. *Int J Cancer J Int Cancer* 2012 May; 130(9):2111–7.
- 255 [12] Chaiwongkot A, Pientong C, Ekalaksananan T, Kongyingyoes B, Thinkhamrop J, Yuenyao P, et
256 al. Evaluation of primers and PCR performance on HPV DNA screening in normal and low grade
257 abnormal cervical cells. *Asian Pac J Cancer Prev APJCP* 2007 Apr-Jun; 8(2):279–82.
- 258 [13] Evans MF, Adamson CS, Simmons-Arnold L, Cooper K. Touchdown General Primer
259 (GP5+/GP6+) PCR and optimized sample DNA concentration support the sensitive detection of
260 human papillomavirus. *BMC Clin Pathol* 2005 Nov; 5(1):10.
- 261 [14] Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for
262 women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-
263 based study in routine clinical practice. *Lancet Oncol* 2011 Jul; 12(7):663–72.
- 264 [15] Meijer CJ, Rozendaal L, Voorhorst FJ, Verheijen R, Helmerhorst TJ, Walboomers JM. Human
265 papillomavirus and screening for cervical cancer: state of art and prospects. *Ned Tijdschr Geneesk*
266 2000 Aug; 144(35):1675–9.
- 267 [16] Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human
268 Papillomavirus Testing in the Prevention of Cervical Cancer. *JNCI J Natl Cancer Inst* 2011 Mar;
269 103(5):368–83.
- 270 [17] Elfstrom KM, Smelov V, Johansson ALV, Eklund C, Naucier P, Arnheim-Dahlstrom L, et al. Long
271 term duration of protective effect for HPV negative women: follow-up of primary HPV screening
272 randomised controlled trial. *BMJ* 2014 Jan; 348(1):g130–g130.
- 273 [18] Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based
274 screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled
275 trials. *The Lancet* 2014 Feb; 383(9916):524–32.
- 276 [19] Lazcano-Ponce E, Lőrincz AT, Torres L, Salmerón J, Cruz A, Rojas R, et al. Specimen self-
277 collection and HPV DNA screening in a pilot study of 100,242 women. *Int J Cancer* 2014 Jul;
278 135(1):109–16.
- 279 [20] Munoz M, Camargo M, Soto-De Leon SC, Sanchez R, Pineda-Pena AC, Perez-Prados A, et al.
280 Classical Molecular Tests Using Urine Samples as a Potential Screening Tool for Human
281 Papillomavirus Detection in Human Immunodeficiency Virus-Infected Women. *J Clin Microbiol* 2013
282 Nov; 51(11):3688–93.
- 283 [21] Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. *The Lancet* 2014 Feb;
284 383(9916):493-494
- 285 [22] Dijkstra MG, Snijders PJF, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJLM. Cervical cancer
286 screening: on the way to a shift from cytology to full molecular screening. *Ann Oncol* 2014 May;
287 25(5):927–35.

288 [23] Park IU, Wojtal N, Silverberg MJ, Bauer HM, Hurley LB, Manos MM. Cytology and Human
 289 Papillomavirus Co-Test Results Preceding Incident High-Grade Cervical Intraepithelial Neoplasia.
 290 PLoS ONE 2015 Mar; 10(3):e0118938.

291 [24] Fowotade A and Manga MM. Utilization of Human papillomavirus (HPV) DNA detection for
 292 cervical cancer screening in developing countries: A myth or reality. Afr J Microbiol Res 2013 May;
 293 7(20):2135–9.

294 [25] Dalstein V, Riethmuller D, Prétet J-L, Le Bail Carval K, Sautière J-L, Carbillet J-P, et al.
 295 Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions:
 296 A longitudinal French cohort study. Int J Cancer 2003 Sept; 106(3):396–403.

297 [26] Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. An Association of
 298 Cervical Inflammation with High-Grade Cervical Neoplasia in Women Infected with Oncogenic Human
 299 Papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 2001 Oct; 10(10):1021–7.

300 [27] Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, et
 301 al. Cytological regression and clearance of high-risk human papillomavirus in women with an
 302 abnormal cervical smear. The Lancet 2001 Nov; 358(9295):1782–3.

303 [28] Ratnam S, Franco EL, Ferenczy A. Human Papillomavirus Testing for Primary Screening of
 304 Cervical Cancer Precursors. Cancer Epidemiol Biomarkers Prev 2000 Sep; 9(9):945–51.

305

306

307